Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 July 1996

Caffeine clearance in patients with primary biliary cirrhosis

Frantisek Perlik, Martin Gilar, Marie Brodanova

Med Sci Monit 1996; 2(4): CR457-460 :: ID: 499946


The clinical value and the sensitivity of saliva caffeine clearance measurement was evaluated as an indicator of liver metabolic capacity in patients with primary biliary cirrhosis (PBC). Saliva test was performed in 12 female patients with PBC and 8 healthy female volunteers. After a 48 hour caffeine exclusion period two doses of 140 mg of caffeine separated by a 4 hour interval were administered orally. Saliva samples were taken 6 and 14 hours later. Caffeine concentrations were measured by high-performance liquid chromatography. Pharmacokinetic parameters were calculated by the fitting procedure of the Bayesian feedback method. There was a significant increase of caffeine half-life in patients with PBC with the mean (SD) value of 5.47 (1.33) hours as compared to that in healthy controls - 4.5 (0.69) hours. The correlation between the pharmacokinetic parameters of caffeine (half-life, clearance and volume of distribution) was statistically significant (p < 0.05) both with the prothrombin ratio and staging, based on morphologic findings in the PBC group. There was no significant correlation neither between the pharmacokinetic parameters of caffeine and conventional liver function tests, nor between the pharmacokinetic parameters and galactose elimination capacity (GEC). Our results suggest that caffeine clearance, like GEC, quantitates a very particular enzymatic reaction which may not be representative for the functional capacity of the entire organ. Thus, a simplified caffeine clearance test represents a helpful additional criterion for the assessment of hepatic function in patients with PBC.

Keywords: primary biliary cirrhosis, caffeine clearance, Bayesian estimate

Add Comment 0 Comments


01 May 2024 : Editorial  

Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)

Dinah V. Parums

DOI: 10.12659/MSM.944927

Med Sci Monit 2024; 30:e944927

In Press

Clinical Research  

Differential Inflammatory Responses in Adult and Pediatric COVID-19 Patients: Implications for Long-Term Co...

Med Sci Monit In Press; DOI: 10.12659/MSM.944052  

Clinical Research  

Effectiveness of Shoulder Taping in Treating Hemiplegic Shoulder Subluxation: A Randomized Controlled Study...

Med Sci Monit In Press; DOI: 10.12659/MSM.944222  

Clinical Research  

Comparison of Fentanyl, Ketamine, and Lidocaine Combined with Propofol Anesthesia in Patients with Crohn Di...

Med Sci Monit In Press; DOI: 10.12659/MSM.944116  

Database Analysis  

ANXA5: A Key Regulator of Immune Cell Infiltration in Hepatocellular Carcinoma

Med Sci Monit In Press; DOI: 10.12659/MSM.943523  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799


14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990


16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387


01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952


Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750